KLRS Kalaris Therapeutics, Inc. - Common Stock
$4,10
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 11, 2026
52W-Spanne
$2–$12
19% of range
Analystenbewertung
STRONG BUY
14 analysts
Kursziel
$19
+356% upside
P/E (TTM)
-1.4
ROE
-65.8%
Nettogewinnmarge
—
KLRS Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$4.10
Marktkapitalisierung
$94M
P/E (TTM)
-1.4
EPS (TTM)
$-2.85
Umsatz (TTM)
—
Dividendenrendite
—
ROE
-65.8%
Verschuldungsgrad
—
52W-Spanne
$2 – $12
KLRS Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
—
2019-12-31
→
2019-12-31
EPS
$-2.85
2021-12-31
→
2025-12-31
Freier Cashflow
$-39M
2020-12-31
→
2025-12-31
Margen
—
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
KLRS
Peer-Median
P/E (TTM)
-1.4
2.6
P/B (K/B)
1.2
3.1
Price / FCF (Kurs / FCF)
-2.4
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
KLRS
Peer-Median
ROA
-67.9%
-60.9%
ROE
-65.8%
-99.5%
ROIC
-58.6%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
KLRS
Peer-Median
Current Ratio (Liquiditätsgrad)
12.2
2.6
Quick Ratio
12.1
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
KLRS
Peer-Median
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
KLRS
Peer-Median
KLRS Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
14 Analysten
- Starker Kauf 6 42,9%
- Kauf 6 42,9%
- Halten 2 14,3%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
7 Analysten · 2026-08-19
Median
$20.00
← Unter allen Zielen
$4.10
Tief
$7.00
Hoch
$25.00
Median-Ziel
$20.00
+387,8%
Mittelwert-Ziel
$18.71
+356,4%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-0.06%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 31. März 2026 | $-0.46 | $-0.53 | 0.07% |
| 31. Dezember 2025 | $-0.51 | $-0.54 | 0.03% |
| 30. September 2025 | $-0.64 | $-0.67 | 0.03% |
| 30. Juni 2025 | $-0.61 | $-0.53 | -0.08% |
| 31. März 2025 | $-2.52 | $-0.79 | -1.7% |
| 30. Juni 2024 | $-1.15 | $-2.46 | 1.3% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| KLRS | $193M | -3.0 | — | — | -65.8% | — |
| FBIO | — | — | — | — | — | — |
| GANX | $135M | -5.3 | -60.6% | — | -181.1% | — |
| RLYB | $4M | -0.4 | 34.9% | -1046.4% | -17.3% | — |
| ICCC | — | -51.2 | 4.3% | — | — | — |
| ACRV | $76M | -1.2 | — | — | -61.0% | — |
| ATRA | $132M | 7.0 | -6.3% | 27.1% | -88.9% | — |
| ACET | — | -0.5 | — | — | — | — |
| SERA | — | -4.4 | 5.2% | -39417.3% | -39.0% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $165.0K | |
| R&D Expense | $31M | $45M | $133M | $119M | $121M | $50M | $16M | |
| SG&A Expense | $15M | $7M | $48M | $52M | $49M | $22M | $11M | |
| Operating Expenses | $46M | $52M | $200M | $171M | $170M | $71M | $27M | |
| Operating Income | $-46M | $-52M | $-200M | $-171M | $-170M | $-71M | $-27M | |
| Interest Expense | $1M | $3M | · | · | · | · | · | |
| Interest Income | · | $5M | $6M | $2M | $1M | $1M | $2M | |
| Other Non-op | $3M | $188.0K | $4M | $351.0K | $-2M | $195.0K | $797.0K | |
| Pretax Income | $-43M | $-69M | $-191M | $-169M | $-171M | $-70M | $-24M | |
| Income Tax | $0 | $0 | $-126.0K | $-265.0K | $1M | · | · | |
| Net Income | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | $-24M | |
| EPS (Basic) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| EPS (Diluted) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| Shares (Basic) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| Shares (Diluted) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| EBITDA | $-46M | $-65M | $-200M | $-170M | · | $-71M | · |
Bilanz 21
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $98M | $2M | $90M | $106M | $202M | $123M | $61M | |
| Short-term Investments | $20M | $0 | $94M | $128M | $46M | $234M | $65M | |
| Prepaid Expense | $827.0K | $967.0K | $3M | $7M | $5M | $5M | $676.0K | |
| Current Assets | $119M | $3M | $188M | $243M | $253M | $361M | $127M | |
| PP&E (Net) | · | · | · | $930.0K | $2M | $812.0K | $350.0K | |
| PP&E (Gross) | · | · | $2M | $2M | $2M | $904.0K | $369.0K | |
| Accum. Depreciation | · | · | · | $1M | $281.0K | $92.0K | $19.0K | |
| Other Non-current Assets | $953.0K | $410.0K | $122.0K | $612.0K | $1M | · | · | |
| Total Assets | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Accounts Payable | $1M | $2M | $7M | $3M | $8M | $963.0K | $630.0K | |
| Accrued Liabilities | · | $5M | $10M | $14M | $20M | $8M | $5M | |
| Current Liabilities | $10M | $25M | $28M | $24M | $38M | $12M | $9M | |
| Capital Leases | $1M | $0 | $17M | $28M | $23M | $5M | $9M | |
| Total Liabilities | $43M | $57M | $45M | $53M | $61M | $18M | $18M | |
| Common Stock | $2.0K | $0 | $0 | $9.0K | $7.0K | $7.0K | · | |
| Paid-in Capital | $239M | $20M | $802M | $691M | $522M | $478M | $4M | |
| Retained Earnings | $-160M | $-117M | $-656M | $-466M | $-297M | $-125M | $-55M | |
| AOCI | $6.0K | $0 | $-62.0K | $-468.0K | $-155.0K | $-112.0K | $68.0K | |
| Stockholders' Equity | $79M | $-97M | $-45M | $225M | $225M | $353M | $-52M | |
| Liabilities + Equity | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Shares Outstanding | 22,902,418 | 1,356,431 | 4,962,997 | 93,093,243 | 63,565,886 | 61,931,255 | 2,099,740 |
Cashflow 15
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $398.0K | $723.0K | $189.0K | $73.0K | $19.0K | |
| Stock-based Comp | $2M | $895.0K | $41M | $41M | $44M | $9M | $3M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | $10M | · | · | · | · | · | |
| Other Non-cash | · | · | $25M | $-15M | · | $-529.0K | · | |
| Operating Cash Flow | $-38M | $-21M | $-124M | $-142M | $-106M | $-61M | $-20M | |
| CapEx | $200.0K | · | · | · | $26.0K | $235.0K | $339.0K | |
| Investing Cash Flow | $-20M | $95M | $38M | $-80M | $186M | $-169M | $-65M | |
| Stock Issued | $42M | · | · | $126M | · | · | · | |
| Net Stock Activity | $42M | · | · | $126M | · | · | · | |
| Financing Cash Flow | $155M | $19M | $70M | $127M | $232.0K | $292M | $121M | |
| Net Change in Cash | $97M | $-2M | $-16M | $-96M | $80M | $62M | $36M | |
| Taxes Paid | $0 | $0 | $220.0K | $613.0K | · | · | · | |
| Free Cash Flow | $-39M | · | · | · | · | $-61M | · | |
| Levered FCF | $-40M | · | · | · | · | · | · |
Rentabilität 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| ROA | -67.9% | -38.0% | -81.4% | -59.9% | · | -27.4% | · | |
| ROE | -65.8% | -491.2% | -111.6% | -70.6% | · | -19.2% | · | |
| ROIC | -58.6% | -57.8% | -137.0% | -76.1% | · | · | · |
Liquidität & Solvenz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.2 | 22.6 | 6.6 | 10.0 | · | 29.4 | · | |
| Quick Ratio | 12.1 | 22.6 | 6.5 | 9.6 | · | 29.0 | · | |
| Interest Coverage | -32.0 | · | · | · | · | · | · |
Bewertung (TTM) 8
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | · | |
| Market Cap | $193M | $49M | $1.79B | $10.98B | · | $54.75B | · | |
| P/E | -3.0 | -0.2 | -0.4 | -53.6 | -108.6 | · | · | |
| P/B | 2.5 | 0.4 | 12.2 | 48.9 | · | 155.1 | · | |
| P / Tangible Book | 2.5 | · | · | 48.9 | 84.0 | 155.1 | · | |
| P / Cash Flow | -5.0 | -0.7 | -14.3 | -77.3 | · | -900.4 | · | |
| P / FCF | -5.0 | · | · | · | · | -896.9 | · | |
| Earnings Yield | -33.8% | -535.9% | -269.1% | -1.9% | -0.92% | · | · |
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $9M | $8M | $7M | $9M | $8M | $6M | $4M | $36M | $3M | $2M | $33M | $34M | $35M | $31M | $28M | $30M | |
| SG&A Expense | $3M | $4M | $4M | $4M | $4M | $4M | $3M | $2M | $976.0K | $602.0K | $10M | $13M | $12M | $13M | $12M | $13M | |
| Operating Expenses | $12M | $12M | $11M | $13M | $12M | $10M | $7M | $38M | $4M | $3M | $62M | $47M | $47M | $43M | $40M | $43M | |
| Operating Income | $-12M | $-12M | $-11M | $-13M | $-12M | $-10M | $-7M | $-38M | $-4M | $-3M | $-62M | $-47M | $-47M | $-43M | $-40M | $-43M | |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1M | $1M | $815.0K | $499.0K | $78.0K | · | · | · | · | · | · | |
| Interest Income | · | · | · | · | · | · | · | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $898.0K | $668.0K | |
| Other Non-op | $871.0K | $977.0K | $803.0K | $847.0K | $906.0K | $193.0K | $64.0K | $31.0K | $66.0K | $27.0K | $1M | $1M | $521.0K | $723.0K | $986.0K | $210.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | $-60M | $-44M | $-45M | · | $-39M | $-42M | |
| Income Tax | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-126.0K | $0 | $0 | $0 | $-415.0K | $0 | |
| Net Income | $-12M | $-11M | $-10M | $-12M | $-11M | $-10M | $-22M | $-38M | $-6M | $-3M | $-60M | $-44M | $-45M | $-41M | $-38M | $-42M | |
| EPS (Basic) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| EPS (Diluted) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| Shares (Basic) | 23,797,306 | 23,723,618 | -26,188,317 | 18,701,708 | 18,701,286 | 4,053,140 | -2,654,598 | 1,352,265 | 1,325,706 | 1,312,552 | -297,299,471 | 113,894,188 | 94,625,837 | 93,303,672 | -136,754,517 | 84,948,837 | |
| Shares (Diluted) | 23,797,306 | 23,723,618 | -26,188,317 | 18,701,708 | 18,701,286 | 4,053,140 | -2,654,598 | 1,352,265 | 1,325,706 | 1,312,552 | -297,299,471 | 113,894,188 | 94,625,837 | 93,303,672 | -136,754,517 | 84,948,837 | |
| EBITDA | $-12M | $-12M | · | $-13M | $-12M | $-10M | · | $-6M | $-8M | $-32M | · | $-47M | $-47M | $-43M | · | $-43M |
Bilanz 20
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $34M | $98M | $42M | $88M | $101M | $2M | $117M | $105M | $86M | $90M | $96M | $197M | $116M | $106M | $124M | |
| Short-term Investments | $50M | $63M | $20M | $35M | · | · | $0 | $5M | $25M | $54M | $94M | $118M | $50M | $87M | $128M | $140M | |
| Prepaid Expense | $2M | $861.0K | $827.0K | $1M | $3M | $1M | $967.0K | $626.0K | $230.0K | $771.0K | $3M | $6M | $5M | $7M | $7M | $6M | |
| Current Assets | $96M | $98M | $119M | $78M | $92M | $102M | $3M | $123M | $130M | $141M | $188M | $220M | $253M | $212M | $243M | $272M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | $673.0K | $759.0K | $844.0K | $930.0K | $943.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | · | |
| Other Non-current Assets | $2M | $2M | $953.0K | $976.0K | $691.0K | $410.0K | $410.0K | · | · | · | $122.0K | $1M | $684.0K | $490.0K | $612.0K | $734.0K | |
| Total Assets | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Accounts Payable | $1M | $905.0K | $1M | $494.0K | $4M | $2M | $2M | $51.0K | $110.0K | $765.0K | $7M | $4M | $5M | $4M | $3M | $5M | |
| Accrued Liabilities | · | · | · | · | · | · | · | $1M | $2M | $5M | $10M | $16M | $17M | $12M | $14M | $14M | |
| Current Liabilities | $9M | $8M | $10M | $6M | $8M | $7M | $25M | $1M | $2M | $8M | $28M | $33M | $31M | $25M | $24M | $21M | |
| Capital Leases | $1M | $1M | $1M | $1M | · | · | $0 | · | $8M | $16M | $17M | $20M | $23M | $26M | $28M | $20M | |
| Total Liabilities | $42M | $41M | $43M | $39M | $40M | $39M | $57M | $1M | $11M | $24M | $45M | $53M | $54M | $51M | $53M | $40M | |
| Common Stock | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $0 | $11.0K | $11.0K | $11.0K | $0 | $11.0K | $11.0K | $9.0K | $9.0K | $9.0K | |
| Paid-in Capital | $240M | $239M | $239M | $192M | $191M | $191M | $20M | $818M | $813M | $807M | $802M | $792M | $782M | $701M | $691M | $681M | |
| Retained Earnings | $-182M | $-171M | $-160M | $-150M | $-138M | $-127M | $-117M | $-697M | $-693M | $-686M | $-656M | $-596M | $-552M | $-507M | $-466M | $-428M | |
| AOCI | $-73.0K | $-49.0K | $6.0K | $6.0K | · | · | $0 | $-134.0K | $-139.0K | $-138.0K | $-62.0K | $-200.0K | $-225.0K | $-301.0K | $-468.0K | $-563.0K | |
| Stockholders' Equity | $58M | $69M | $79M | $42M | $53M | $64M | $-97M | $121M | $120M | $120M | $146M | $195M | $229M | $194M | $225M | $253M | |
| Liabilities + Equity | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Shares Outstanding | 23,804,981 | 22,992,291 | 22,902,418 | 18,702,418 | 18,702,418 | 18,702,418 | 1,356,431 | 115,438,119 | 115,312,411 | 114,881,765 | 4,962,997 | 113,966,594 | 113,716,018 | 93,427,990 | 93,093,243 | 92,640,109 |
Cashflow 12
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | $141.0K | $86.0K | $85.0K | $86.0K | $86.0K | $85.0K | |
| Stock-based Comp | $644.0K | $580.0K | $333.0K | $638.0K | $591.0K | $374.0K | $280.0K | $-10M | $-5M | $31.0K | $10M | $10M | $10M | $10M | $9M | $11M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | $0 | |
| Restructuring | · | · | · | · | · | · | · | $100.0K | $500.0K | $10M | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | · | · | · | · | $-1M | · | · | |
| Operating Cash Flow | $-11M | $-12M | $-7M | $-11M | $-13M | $-7M | $-8M | $43M | $36M | $-5M | $-31M | $-34M | $-27M | $-32M | $-32M | $-35M | |
| CapEx | · | · | $17.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $20M | $-50M | $15M | · | · | · | · | $20M | $30M | $40M | $25M | $-67M | $38M | $42M | $14M | $-39M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Financing Cash Flow | $-377.0K | $-2M | $48M | $0 | $0 | $107M | $8M | $12M | $5M | $7M | $11.0K | $0 | · | · | $292.0K | $126M | |
| Net Change in Cash | $9M | $-64M | $56M | $-46M | $-13M | $100M | $-274.0K | $-16M | $7M | $2M | $-6M | $-101M | $81M | $10M | $-18M | $53M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $-131.0K | $1.0K | · | · | $-390.0K | $0 |
Rentabilität 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -12.0% | -10.2% | · | -11.7% | -10.1% | -8.2% | · | -2.2% | -2.9% | -15.6% | · | -16.3% | -18.8% | -17.3% | · | -13.8% | |
| ROE | -20.8% | -16.4% | · | -14.6% | -13.1% | -11.1% | · | -2.6% | -3.5% | -19.3% | · | -19.7% | -23.4% | -21.4% | · | -16.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -24.0% | -20.6% | · | · | · |
Liquidität & Solvenz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.0 | 12.2 | · | 12.9 | 12.0 | 14.3 | · | 86.8 | 55.1 | 18.5 | · | 6.7 | 8.3 | 8.5 | · | 13.1 | |
| Quick Ratio | 10.7 | 12.0 | · | 12.7 | 11.6 | 14.1 | · | 86.3 | 54.9 | 18.4 | · | 6.5 | 8.1 | 8.1 | · | 12.7 | |
| Interest Coverage | · | · | · | · | · | -7.2 | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-46M | $-44M | · | $-72M | $-65M | $-57M | · | $-91M | $-99M | $-134M | · | $-173M | $-173M | $-172M | · | $-176M | |
| Market Cap | $97M | $133M | · | $108M | $50M | $150M | · | $2.15B | $1.92B | $1.99B | · | $5.64B | $8.89B | $8.47B | · | $16.81B | |
| P/E | -1.9 | -1.4 | · | -0.2 | -0.1 | -0.2 | · | -0.5 | -2.2 | -4.4 | · | -27.3 | -37.1 | -39.1 | · | -69.8 | |
| P/B | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Tangible Book | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Cash Flow | · | -11.5 | · | · | · | -20.2 | · | · | · | -45.0 | · | · | · | -263.6 | · | · | |
| Earnings Yield | -53.8% | -73.3% | · | -552.4% | -1331.5% | -467.5% | · | -190.3% | -46.5% | -22.5% | · | -3.7% | -2.7% | -2.6% | · | -1.4% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Nettoergebnis | $-43M | $-69M | $-190M | $-169M | $-172M |
| Verwässerte EPS | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 12.2 | 22.6 | 6.6 | 10.0 | — |
| Quick Ratio | 12.1 | 22.6 | 6.5 | 9.6 | — |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-39M | — | — | — | — |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 58 Einreicher · $74.1M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 13 (+1 vs. Vorquartal) | 11 (+4 vs. Vorquartal) | 15 (0 vs. Vorquartal) | 9 (+1 vs. Vorquartal) | -333K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | $52.426.382 | 12.881.175 | 70,79% | Aktien |
| RTW INVESTMENTS, LP | $5.291.000 | 1.300.000 | 7,14% | Aktien |
| Alyeska Investment Group, L.P. | $2.330.836 | 572.687 | 3,15% | Aktien |
| VANGUARD GROUP INC | $2.155.137 | 255.348 | 2,91% | Aktien |
| Siren, L.L.C. | $1.773.698 | 435.798 | 2,40% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.622.758 | 398.712 | 2,19% | Aktien |
| Ikarian Capital, LLC | $1.465.201 | 360.000 | 1,98% | Aktien |
| UBS Group AG | $1.066.873 | 262.131 | 1,44% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $607.859 | 149.351 | 0,82% | Aktien |
| Woodline Partners LP | $407.000 | 100.000 | 0,55% | Aktien |
| ADAR1 Capital Management, LLC | $407.000 | 100.000 | 0,55% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $404.332 | 99.306 | 0,55% | Aktien |
| WHI TRUST Co LLC | $396.797 | 97.493 | 0,54% | Aktien |
| CITADEL ADVISORS LLC | $389.792 | 95.772 | 0,53% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $375.502 | 92.261 | 0,51% | Aktien |
| Verdad Advisers, LP | $326.809 | 80.297 | 0,44% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $269.349 | 66.179 | 0,36% | Aktien |
| Fortis Capital Advisors, LLC | $162.800 | 40.000 | 0,22% | Aktien |
| Belpointe Asset Management LLC | $162.800 | 40.000 | 0,22% | Aktien |
| Pale Fire Capital SE | $161.278 | 39.626 | 0,22% | Aktien |
| Squarepoint Ops LLC | $157.814 | 38.775 | 0,21% | Aktien |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $132.275 | 32.500 | 0,18% | Aktien |
| Stonepine Capital Management, LLC | $122.597 | 30.122 | 0,17% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $122.128 | 30.007 | 0,16% | Aktien |
| Trexquant Investment LP | $121.030 | 29.737 | 0,16% | Aktien |
| STATE STREET CORP | $107.896 | 26.510 | 0,15% | Aktien |
| NORTHERN TRUST CORP | $105.165 | 25.839 | 0,14% | Aktien |
| Velan Capital Investment Management LP | $101.750 | 25.000 | 0,14% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $97.057 | 23.847 | 0,13% | Aktien |
| WealthTrust Asset Management, LLC | $83.093 | 20.416 | 0,11% | Aktien |
| Independent Advisor Alliance | $73.769 | 18.125 | 0,10% | Aktien |
| RBF Capital, LLC | $70.781 | 17.391 | 0,10% | Aktien |
| MORGAN STANLEY | $69.642 | 17.111 | 0,09% | Aktien |
| Quadrature Capital Ltd | $67.265 | 16.527 | 0,09% | Aktien |
| GOLDMAN SACHS GROUP INC | $65.340 | 16.054 | 0,09% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57.879 | 14.221 | 0,08% | Aktien |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $50.875 | 12.500 | 0,07% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $48.168 | 11.835 | 0,07% | Aktien |
| MARSHALL WACE, LLP | $42.068 | 10.336 | 0,06% | Aktien |
| Sigma Planning Corp | $41.380 | 10.167 | 0,06% | Aktien |
| FMR LLC | $31.770 | 7.806 | 0,04% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $28.490 | 7.000 | 0,04% | Aktien |
| Integrated Wealth Concepts LLC | $20.350 | 5.000 | 0,03% | Aktien |
| Tower Research Capital LLC (TRC) | $10.419 | 2.560 | 0,01% | Aktien |
| Steward Partners Investment Advisory, LLC | $9.015 | 2.215 | 0,01% | Aktien |
| BlackRock, Inc. | $7.021 | 1.725 | 0,01% | Aktien |
| Vanguard Global Advisers, LLC | $2.951 | 725 | 0,00% | Aktien |
| BARCLAYS PLC | $1.233 | 303 | 0,00% | Aktien |
| Strengthening Families & Communities, LLC | $1.091 | 268 | 0,00% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $212 | 52 | 0,00% | Aktien |
| Parallel Advisors, LLC | $199 | 49 | 0,00% | Aktien |
| JPMORGAN CHASE & CO | $194 | 46 | 0,00% | Aktien |
| HRT FINANCIAL LP | $55 | 13.723 | 0,00% | Aktien |
| HARBOUR INVESTMENTS, INC. | $53 | 13 | 0,00% | Aktien |
| Virtu Financial LLC | $44 | 10.845 | 0,00% | Aktien |
| Caitong International Asset Management Co., Ltd | $28 | 7 | 0,00% | Aktien |
| SBI Securities Co., Ltd. | $20 | 5 | 0,00% | Aktien |
| ROYAL BANK OF CANADA | $0 | 12 | 0,00% | Aktien |
Unternehmensinsider 30 Insider · 13 Führungskräfte · 20 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Andrew Oxtoby | President and Chief Executive Officer | 19. März 2026 A | — | 0 | 0 | $0 |
| Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | 21. Februar 2025 S | 49.129 | 0 | 0 | $0 |
| Diana Brainard | Chief Executive Officer | 19. November 2024 S | 723.363 | 0 | 0 | $0 |
| Liisa Ann Bayko | Chief Financial Officer | 20. Juli 2026 A | — | 0 | 0 | $0 |
| Matthew Gall | Chief Financial Officer | 19. März 2026 A | — | 0 | 0 | $0 |
| Matthew Feinsod | Chief Medical Officer | 19. März 2026 A | 4.030 | 0 | 0 | $0 |
| Brett R Hagen | Chief Accounting Officer | 19. März 2026 A | 0 | 0 | 1 | $-12.869 |
| Edward Miller | General Counsel | 21. Februar 2025 S | 6.517 | 0 | 0 | $0 |
| Cintia Piccina | Chief Commercial Officer | 3. Juli 2023 A | 147.000 | 0 | 0 | $0 |
| Ann M. Leen | Chief Scientific Officer | 2. Februar 2023 A | 124.006 | 0 | 0 | $0 |
| Jeroen B Van Beek | Chief Commercial Officer | 16. November 2022 S | 333.726 | 0 | 0 | $0 |
| Ercem Atillasoy | This Form 4/A is being filed correct the transaction dates reported in the original Form 4 filed on October 24, 2022. Officer T | 21. Oktober 2022 S | 131.372 | 0 | 0 | $0 |
| Agustin Melian | Chief Medical Officer | 4. Oktober 2021 S | 453.529 | 0 | 0 | $0 |
| Laurie Keating | Direktor | 1. August 2026 A | — | 0 | 0 | $0 |
| Napoleone Ferrara | Direktor | 3. Juni 2026 A | 504.000 | 0 | 0 | $0 |
| Michael Dybbs | Direktor | 3. Juni 2026 A | — | 0 | 0 | $0 |
| Morana Jovan-Embiricos | Direktor | 3. Juni 2026 A | 100.197 | 0 | 0 | $0 |
| David Hallal | Direktor | 3. Juni 2026 A | 2.143.662 | 0 | 0 | $0 |
| Anthony P Adamis | Direktor | 3. Juni 2026 A | — | 0 | 0 | $0 |
| Srinivas Akkaraju | Direktor | 3. Juni 2026 A | 11.444.503 | 0 | 0 | $0 |
| Leone D Patterson | Direktor | 3. Juni 2026 A | — | 0 | 0 | $0 |
| Samir Chandrakant Patel | Direktor | 10. April 2025 A | 100.800 | 0 | 0 | $0 |
| Derek N. Adams | Direktor | 6. Juni 2024 A | 70.000 | 0 | 0 | $0 |
| Malcolm Brenner | Direktor | 6. Juni 2024 A | 100.197 | 0 | 0 | $0 |
| Juan Vera | Direktor | 6. Juni 2024 A | 2.409.928 | 0 | 0 | $0 |
| Shawn Tomasello | Direktor | 6. Juni 2024 A | 70.000 | 0 | 0 | $0 |
| Jeffrey S Bornstein | Direktor | 6. Juni 2024 A | 110.197 | 0 | 0 | $0 |
| ElevateBio, LLC | Direktor | 28. Juli 2022 A | 16.674.766 | 0 | 0 | $0 |
| ANSBERT GADICKE | Direktor | 28. Juli 2022 A | 16.674.766 | 0 | 0 | $0 |
| John Robert Wilson | Direktor | 25. Mai 2021 A | 3.164.954 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC, Srinivas Akkaraju ×4 Einreichungen | 22. Mai 2026 | 54,20% | Änderung | — | SEC |
| ElevateBio, LLC (2) | 5. August 2022 | — | Erste Einreichung | — | SEC |
| F2 MG Ltd. (2), F2-TPO Investments, LLC (2), F2 MC, LLC (2), F2 Capital I 2020 LLC (2), F2 Bioscience AV 2022 LLC (2), Globeways Holdings Ltd. (2), Globeways Holdings II Ltd. (2), Morana Jovan-Embiricos (2) | 5. August 2022 | — | Erste Einreichung | — | SEC |
| ElevateBio LLC (2) | 13. August 2020 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 3 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.